Related Experiment Videos
Apoptosis or necrosis for tumor immunotherapy: what's in a name?
Abstract:
Here we discuss how the mechanisms by which tumor cells are killed in vivo by gene transfer affects their immunogenicity. Our own work has shown that necrotic cell death induces immunological activation signals which recruit, load, activate and mature appropriate subsets of antigen-presenting cells. In contrast, for apoptotic cell death to be immunogenic, signals additional to cell death alone must be provided within the milieu of the dying tumor. Our conclusion is that the immunogenicity of tumor killing is determined by a combination of factors, including the mechanism of killing, the levels of cell death, the local environment that exists within the dying tumor and, as a result, the nature of the immune/scavenger cells which are present at the time of antigen release. Knowledge of how these factors can influence the immune system and lead to the breaking of tolerance to tumor-associated antigens, can potentially be exploited in the design of effective immunotherapies for cancer using gene transfer.
Insights
Tumor cell death via gene transfer can be immunogenic. Necrotic cell death activates immune cells, while apoptotic cell death requires additional signals for immunogenicity, crucial for cancer immunotherapy development.
Area of Science:
- Immunology
- Cancer Biology
- Gene Therapy
Background:
- Tumor cell death mechanisms influence anti-tumor immune responses.
- Gene transfer strategies are explored for cancer treatment.
Purpose of the Study:
- To investigate how tumor cell killing mechanisms affect immunogenicity in vivo.
- To understand the role of cell death type and tumor microenvironment in immune activation.
Main Methods:
- Discussion of in vivo gene transfer mechanisms.
- Analysis of necrotic versus apoptotic cell death signaling.
Main Results:
- Necrotic cell death inherently induces immunological activation signals.
- Apoptotic cell death requires additional signals for immunogenicity.
- Tumor immunogenicity depends on killing mechanism, cell death levels, and local environment.
Conclusions:
- The immunogenicity of tumor killing is multifactorial.
- Understanding these factors can guide the design of gene transfer-based cancer immunotherapies.
- Breaking immune tolerance to tumor antigens is key for effective treatment.